Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1461258 | 0.96 | KDM1A (0.32) | KDM1A | |
| SCHEMBL741147 | 0.74 | GAA (0.32) | KDM1A | |
| SCHEMBL27558383 | 0.74 | GAA (0.32) | KDM1A | |
| SCHEMBL8796961 | 0.74 | GAA (0.32) | KDM1A | |
| SCHEMBL17419373 | 0.74 | GAA (0.32) | KDM1A | |
| SCHEMBL4206000 | 0.72 | BTK (0.31) | KDM1A | |
| SCHEMBL2561559 | 0.72 | BTK (0.31) | KDM1A | |
| SCHEMBL12987233 | 0.72 | BTK (0.31) | KDM1A | |
| SCHEMBL4197528 | 0.72 | BTK (0.31) | KDM1A | |
| SCHEMBL2557566 | 0.72 | BTK (0.31) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2024-11-14 | — | — | US | disclosed |
| US-20230080520-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2023-03-16 | — | — | US | disclosed |
| US-11278595-B2 | Peptides comprising non-natural amino acids and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20210205415-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC | 2021-07-08 | — | — | US | disclosed |
| US-20200384085-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10772934-B2 | Highly active polypeptides and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10543255-B2 | Peptides comprising non-natural amino acids and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20180193422-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180193423-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2018-07-12 | — | — | US | disclosed |
| EP-2694095-B1 | COMPOSITIONS COMPRISING GLUCAGON ANALOGS AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH INC (US) | 2018-03-07 | — | — | EP | disclosed |
| US-9782454-B2 | Highly active polypeptides and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160045572-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2016-02-18 | — | — | US | disclosed |
| EP-2968469-A2 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | Longevity Biotech, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150051141-A9 | Compositions Comprising Glucagon Analogs And Methods Of Making And Using The Same | LONGEVITY BIOTECH, INC. (US) | 2015-02-19 | — | — | US | disclosed |
| WO-2014145718-A2 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140121154-A1 | Compositions Comprising Glucagon Analogs And Methods Of Making And Using The Same | LONGEVITY BIOTECH, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| EP-2694095-A1 | COMPOSITIONS COMPRISING GLUCAGON ANALOGS AND METHODS OF MAKING AND USING THE SAME | Longevity Biotech, Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| US-20130096050-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2012138941-A1 | COMPOSITIONS COMPRISING GLUCAGON ANALOGS AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| WO-2011133948-A2 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193423-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | APLNR, SCTR, GIPR | KDM1A 4825/4885 |
| US-20200384085-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | APLNR, SCTR, GIPR | KDM1A 4825/4885 |
| US-20180193422-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | KDM1A 4842/4885 |
| US-20230080520-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | APLNR, SCTR, GIPR | KDM1A 4825/4885 |
| US-20160045572-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | APLNR, SCTR, GIPR | KDM1A 4825/4885 |
| US-11278595-B2 | Peptides comprising non-natural amino acids and methods of making and using the same | APLNR, SCTR, GIPR | KDM1A 4825/4885 |
| US-20210205415-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | KDM1A 4842/4885 |
| US-20150051141-A9 | Compositions Comprising Glucagon Analogs And Methods Of Making And Using The Same | GLP1R, IAPP, GIPR | KDM1A 4594/4885 |
| US-10772934-B2 | Highly active polypeptides and methods of making and using the same | SCTR, GIPR, APLNR | KDM1A 4842/4885 |
| US-10543255-B2 | Peptides comprising non-natural amino acids and methods of making and using the same | APLNR, SCTR, GIPR | KDM1A 4825/4885 |
| US-20130096050-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | APLNR, SCTR, GIPR | KDM1A 4852/4885 |
| US-20140121154-A1 | Compositions Comprising Glucagon Analogs And Methods Of Making And Using The Same | GLP1R, IAPP, GIPR | KDM1A 4594/4885 |
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | KDM1A 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.